Goldman Sachs’s NovoCure NVCR Stock Holding History

Goldman Sachs’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,000	Closed	-$1.43M	–	6812
2021 Q4	$1.43M	Hold	19,000	–	–	﹤0.01%	4539
2021 Q3	$2.21M	Hold	19,000	–	–	﹤0.01%	4106
2021 Q2	$4.21M	Hold	19,000	–	–	﹤0.01%	3490
2021 Q1	$2.51M	Hold	19,000	–	–	﹤0.01%	3762
2020 Q4	$3.29M	Buy	19,000 +5,000	+36%	+$684K	﹤0.01%	3342
2020 Q3	$1.56M	Buy	+14,000	New	+$1.12M	﹤0.01%	3751
2016 Q1	–	Sell	-30,000	Closed	-$671K	–	7243
2015 Q4	$671K	Buy	+30,000	New	+$717K	﹤0.01%	4666

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Goldman Sachs's NVCR Position: Q1 2026 in Review

Goldman Sachs reduced its NovoCure (NVCR) stake by 37% in Q1 2026, selling an estimated $5.4M and leaving 745,435 shares worth $8.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Goldman Sachs first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $97M in Q3 2017. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Goldman Sachs held 745,435 shares of NovoCure worth $8.13M as of Q1 2026.
Goldman Sachs sold 432,610 NovoCure shares in Q1 2026, an estimated $5.4M.
NovoCure made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3238 holding.
Goldman Sachs first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
Goldman Sachs's NovoCure position peaked at $97M in Q3 2017.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.